Live Breaking News & Updates on Lifesciences Acquisition Corporation

Posted on
185
Frazier Healthcare Partners’ special purpose acquisition corporation, Frazier Lifesciences Acquisition Corporation, announced the pricing of its initial public offering of 12,000,000 units, at a price to the public of $10.00 per unit, for aggregate gross proceeds of $120,000,000. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share. The units are expected to begin trading on the Nasdaq Capital Market on December 9, 2020 under the symbol “FLACU”. The offering is expected to close on December 11, 2020, subject to customary closing conditions.
Frazier Lifesciences Acquisition Corporation, sponsored by a Cayman Islands affiliate of Frazier Life Sciences X, L.P., is a newly incorporated blank check company, incorporated as a Cayman Islands exempted company for the pu ....

United States , North Carolina , Cayman Islands , David Topper , James Topper , Max Nowicki , Michael Bigham , Robert Baltera , Carol Gallagher , Gordon Empey , Prospectus Department , Exchange Commission On , Credit Suisse Securities United States , Frazier Lifesciences Acquisition Corporation , Frazier Life Sciences , Frazier Healthcare Partner , Nasdaq Capital Market , Lifesciences Acquisition Corporation , Managing General Partner , Frazier Healthcare Partners , Chief Executive Officer , Senior Advisor , Chief Financial Officer , General Counsel , Vice President , Senior Associate ,